Foghorn Therapeutics Inc. Payments of Stock Issuance Costs
Foghorn Therapeutics Inc. (FHTX) reported Payments of Stock Issuance Costs of $347.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2026-08-06
- Foghorn Therapeutics Inc. payments of stock issuance costs for the quarter ending 2026-06-30 was $31.00K.
- Foghorn Therapeutics Inc. payments of stock issuance costs for the quarter ending 2026-03-31 was $316.00K.
- Foghorn Therapeutics Inc. payments of stock issuance costs for the quarter ending 2025-12-31 was $0.00.
- Foghorn Therapeutics Inc. payments of stock issuance costs for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Foghorn Therapeutics Inc. payments of stock issuance costs for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Foghorn Therapeutics Inc. payments of stock issuance costs for fiscal 2024 was $585.00K.
- Foghorn Therapeutics Inc. payments of stock issuance costs for fiscal 2023 was $0.00.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|---|
| 2026-06-30 | $31.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $347.00K 10-Q · filed 2026-08-06 | $347.00K derived: sum of 3 quarters · filed 2026-08-06 | $347.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $316.00K 10-Q · filed 2026-05-07 | $316.00K derived: sum of 2 quarters · filed 2026-05-07 | $316.00K derived: sum of 3 quarters · filed 2026-05-07 | $316.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $0.00 derived: sum of 2 quarters · filed 2026-03-11 | $0.00 derived: sum of 3 quarters · filed 2026-08-06 | $0.00 10-K · filed 2026-03-11 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2026-08-06 | $0.00 10-Q · filed 2025-11-05 | $0.00 derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | $0.00 derived: sum of 3 quarters · filed 2026-08-06 | $390.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-05-07 | $390.00K derived: sum of 3 quarters · filed 2026-05-07 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $390.00K derived: sum of 2 quarters · filed 2026-03-11 | $585.00K 10-K · filed 2026-03-11 | |
| 2024-09-30 | $390.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $585.00K 10-Q · filed 2025-11-05 | ||
| 2024-06-30 | $195.00K 10-Q · filed 2025-08-05 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $0.00 derived: sum of 2 quarters · filed 2025-03-06 | $0.00 10-K · filed 2025-03-06 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $0.00 10-Q · filed 2024-11-04 | ||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-08 | |||
| 2020-09-30 | $1.25M 10-Q · filed 2020-12-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |